From newsworthy moments to groundbreaking research, these are the most popular articles in the intravenous immunoglobulin space, published on Pharmacy Times® during 2022.
5. Study: IVIG Should Be Given on Case-by-Case Basis, Based on Lack of Large Trial Evidence
The risk of developing acute renal failure and septic shock were higher for individuals with necrotizing soft-tissue infections treated with immunoglobulins, investigators say. Read More.
4. Subcutaneous Immunotherapy-Induced Antibodies May be Effective Treating Allergic Asthma
Subcutaneous immunotherapy-induced antibodies may serve as a potential allergen-targeted biologics candidate for the treatment of allergic asthma. Read More.
3. IVIG Safe, Effective Treating Pregnant Patients With Severe COVID-19
Intravenous immunoglobulin shows promise as a treatment option for pregnant patients with SARS-CoV-2, influenza, and other respiratory viruses. Read More.
2. IVIG Shows Potential to Reverse Symptoms of Down Syndrome Regression Disorder
Because there is an inflammatory component to Down syndrome regression disorder, it may potentially be reversible with immunotherapy. Read More.
1. High-Dose IVIG Can Improve Outcomes for Individuals with Severe COVID-19 Findings of the study, published in International Immunopharmacology, also show that timing and patient selection is an important factor when administering intravenous immunoglobin. Read More.